Revvity sets its post-Pandemic health strategy, shares on the NYSE in a diversified diagnostics peer group
28.06.2026 - 09:43:53 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 09:43.
Revvity Inc. (US76155R1086) operates on the NYSE with a diversified diagnostics and life sciences toolkit. The company sits in a global peer group that includes names such as Thermo Fisher Scientific and Danaher, both active in laboratory instruments and health diagnostics.
How Revvity positions itself
Revvity emerged from the rebranding of PerkinElmer's applied, food and enterprise services activities and now focuses on precision diagnostics and life sciences tools for clinical and research customers. The portfolio spans assay platforms, imaging systems and analytical instruments used in hospitals, public health laboratories and pharmaceutical research facilities.
The company steers its long-term course via a mix of consumables, instruments and software that aims at recurring revenue streams and integrated workflows. In this way Revvity competes with multinational diagnostics groups that seek to anchor their products in standardized clinical pathways and research protocols worldwide.
Strategy in a post-pandemic diagnostics market
Global diagnostics demand changed markedly after the COVID-19 pandemic, with routine testing volumes normalizing while molecular and genomic methods gained broader adoption in clinical practice. Revvity's strategy leans on this shift by supplying platforms that support high-throughput screening, infectious disease monitoring and oncology biomarker testing in laboratories.
Sector peers such as Thermo Fisher Scientific and Danaher also emphasize comprehensive solutions that combine instruments and consumables, placing Revvity in a competitive landscape shaped by consolidation and technology integration. The company aims for a mix of diagnostic tools and services that support public health programs, hospital laboratories and pharma research projects.
Background and price data on Revvity
Further articles on the Revvity shares plus historical price data and corporate news are available in the dedicated topic section and on the company's investor relations pages.
The product behind the stock
One representative product line at Revvity is its genetic screening and infectious disease assay platforms, which provide laboratories with tests for conditions such as neonatal disorders and respiratory pathogens. These assays are designed for use on standardized instruments, supporting routine diagnostics workflows in hospitals and public health laboratories without entering into stock or price commentary.
Where the stock trades today
The Revvity shares (US76155R1086) trade on the NYSE, with prices quoted in US dollars during regular New York trading hours.
Key data on the Revvity shares
- Company: Revvity Inc.
- ISIN: US76155R1086
- WKN: not available
- Ticker: RVTY
- Trading venue: NYSE
- Price (as of 2026-06-26, 21:59): 107.53 USD
- Market cap: 13.6 billion USD (as of 2026-06-26)
- Sector / industry: Health care equipment & supplies / diagnostics and research tools
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. Investors should consult professional advisers before making investment decisions.
